Tag: Biologics
“Biologics and biosimilars represent Veeda’s second-highest strategic priority after clinical trials”
Binoy Gardi, Managing Director and Group CEO, Veeda Lifesciences shared insights on his latest role and top priorities; the company's latest initiatives, outcomes of key acquisitions and future plans
OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic in...
Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state- of-the-art integratedBiologics and Drug-Device Combination facility
Fitch Ratings revises Biocon Biologics outlook from ‘stable’ to ‘positive’
Fitch said the ‘Positive’ outlook of the Company’s credit rating reflects its expectation of a sustained reduction in Biocon Limited's financial leverage
Samsung Bioepis reaches settlement agreement for Eylea (Aflibercept) biosimilar in Europe...
This agreement enables Samsung Bioepis to launch SB15 in the United Kingdom (UK) from January 2026, in the rest of Europe from April 2026
Budget 2026: OPPI calls ‘Biopharma Shakti’ India’s leap toward global leadership
The Budget’s focused push on biologics and biosimilars, backed by a dedicated biopharma innovation network, was described by Matai as positioning India strongly for the next wave of complex, high-value therapies
S&P Global upgrades Biocon Biologics credit rating to BB+
The upgrade follows Biocon’s recent equity issuance undertaken to settle the compulsorily convertible preference shares (CCPS) issued to Viatris Inc.
Kashiv BioSciences secures Rs 648 crore financing from Union Bank of...
The facility will drive investment in state-of-the-art biologics manufacturing facility in Pipan, Gujarat
Biocon unifies with Biocon Biologics to establish a single global biopharma...
This integration will enable Biocon to leverage the combined strengths of its biosimilars and generics operations across more than 120 countries
Biocon Biologics secures market entry date for Denosumab biosimilars in...
The agreement allows the company to commercialize both its Denosumab biosimilars (Vevzuo® and Evfraxy®) in Europe starting December 2, 2025
Lost in Translation? India’s Biologics R&D Shortfall
Domestic manufacturers have petitioned for tax reliefs—such as income‑tax exemptions on new molecular entities—to incentivize high‑risk R&D